MYUNGMOON PHARM CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,000 KRW | +1.94% |
|
+4.49% | -12.47% |
| Jul. 09 | MYUNGMOON Pharm co.,Ltd announces an Equity Buyback for KRW 300 million worth of its shares. | CI |
| Jul. 09 | MYUNGMOON Pharm co.,Ltd authorizes a Buyback Plan. | CI |
| Sales 2022 | 152B 110M | Sales 2023 | 170B 122M | Capitalization | 76.62B 55.32M |
|---|---|---|---|---|---|
| Net income 2022 | 7.87B 5.68M | Net income 2023 | -4.52B -3.27M | EV / Sales 2022 | 1.12 x |
| Net Debt 2022 | 73.17B 52.83M | Net Debt 2023 | 78.82B 56.91M | EV / Sales 2023 | 0.92 x |
| P/E ratio 2022 |
12.3
x | P/E ratio 2023 |
-17
x | Employees | 281 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.69% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.94% | ||
| 1 week | +4.49% | ||
| Current month | +0.55% | ||
| 1 month | -1.48% | ||
| 3 months | -3.38% | ||
| 6 months | -11.70% | ||
| Current year | -12.47% |
1 week
1 929.00
2 000.00
1 month
1 888.002 100.00
Current year
1 888.002 515.00
1 year
1 888.002 725.00
3 years
1 888.006 400.00
5 years
1 888.0011 750.00
10 years
1 888.0011 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Choon-Sik Park
CEO | Chief Executive Officer | 62 | - |
Seok-Min Woo
CHM | Chairman | 56 | 01-01-31 |
Jang-Ho Lee
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seok-Min Woo
CHM | Chairman | 56 | 01-01-31 |
Yong-Jin Jeong
BRD | Director/Board Member | 59 | - |
Cheol-Han Bae
BRD | Director/Board Member | 72 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-15 | 2,000 | +1.94% | 26,645 |
| 24-07-12 | 1,962 | -0.96% | 22,939 |
| 24-07-11 | 1,981 | +0.56% | 30,402 |
| 24-07-10 | 1,970 | +2.23% | 68,812 |
| 24-07-09 | 1,927 | +0.68% | 53,925 |
End-of-day quote Korea S.E., July 14, 2024
More quotes
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.47% | 47.87M | |
| +63.05% | 854B | |
| +39.42% | 636B | |
| -4.78% | 361B | |
| +17.52% | 324B | |
| +8.43% | 301B | |
| +14.19% | 247B | |
| +5.81% | 230B | |
| +16.77% | 228B | |
| +14.63% | 177B |
- Stock Market
- Equities
- A017180 Stock
